1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
(
- Contribution to journal › Article
-
Mark
Hyaluronic Acid-Conjugated Thermoresponsive Polymer-Based Bioformulation Enhanced Wound Healing and Gut Barrier Repair of a TNBS-Induced Colitis Injury Ex Vivo Model in a Dynamic Perfusion Device
(
- Contribution to journal › Article
- 2023
-
Mark
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients : comparison of retrospective cohorts
(
- Contribution to journal › Article
-
Mark
Long-term outcomes of vedolizumab in inflammatory bowel disease : the Swedish prospective multicentre SVEAH extension study
(
- Contribution to journal › Article
-
Mark
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
(
- Contribution to journal › Article
- 2021
-
Mark
Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study
(
- Contribution to journal › Article
- 2019
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article
- 2012
-
Mark
Targeting T cell migration in inflammatory bowel disease.
(
- Contribution to journal › Article